User profiles for Olav Dalgard
 | Olav DalgardProfessor of medicine, University of Oslo Verified email at medisin.uio.no Cited by 12458 |
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Background The 69th World Health Assembly approved the Global Health Sector Strategy
to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the …
to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the …
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
…, CW Cunningham, LD Abou, O Dalgard… - The Lancet …, 2022 - thelancet.com
Background Since the release of the first global hepatitis elimination targets in 2016, and until
the COVID-19 pandemic started in early 2020, many countries and territories were making …
the COVID-19 pandemic started in early 2020, many countries and territories were making …
EASL recommendations on treatment of hepatitis C: final update of the series☆
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately
71 million chronically infected individuals worldwide. Clinical care for patients with HCV-…
71 million chronically infected individuals worldwide. Clinical care for patients with HCV-…
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
Background and Aim: Decisions on public health issues are dependent on reliable
epidemiological data. A comprehensive review of the literature was used to gather country‐specific …
epidemiological data. A comprehensive review of the literature was used to gather country‐specific …
[HTML][HTML] Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs)
on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …
on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …
EASL recommendations on treatment of hepatitis C 2018
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately
71 million chronically infected individuals worldwide. Clinical care for patients with HCV-…
71 million chronically infected individuals worldwide. Clinical care for patients with HCV-…
Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial
… Dalgard reports grants from Merck, Gilead, and AbbVie during the conduct of the study. Dr.
Gane reports membership in the HCV Scientific Advisory Board and speakers bureau for …
Gane reports membership in the HCV Scientific Advisory Board and speakers bureau for …
CMV drives clonal expansion of NKG2C+ NK cells expressing self‐specific KIRs in chronic hepatitis patients
Natural killer (NK) cells are affected by infection with human cytomegalovirus (HCMV)
manifested by increased expression of the HLA‐E binding activating receptor NKG2C. We here …
manifested by increased expression of the HLA‐E binding activating receptor NKG2C. We here …
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial
Background Despite revised guidelines that no longer exclude people who inject drugs (PWID)
from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to treat …
from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to treat …
[PDF][PDF] Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study
O Dalgard, K Bjøro, KB Hellum, B Myrvang… - …, 2004 - Wiley Online Library
The aim of this study was to determine the efficacy of 14 weeks of treatment in patients infected
with hepatitis C virus (HCV) genotype 2 or 3 who achieve early virological response (EVR…
with hepatitis C virus (HCV) genotype 2 or 3 who achieve early virological response (EVR…
